Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52


Résultats oncologiques du traitement des TVES≤pT2 de l'uretère pelvien par néphro-urétérectomie, résection segmentaire et chirurgie endoscopique : résultats d'une étude multicentrique européenne.

Nison L, Colin P, Remzi M, Shariat S, Klatte T, Yakoubi R, Bozzini G, Capitanio U, Babjuk M, Merseburger A, Cha E, Fritsche H, Novara G, Montorsi F, Hora M, Roupret M.

Prog Urol. 2015 Nov;25(13):807. doi: 10.1016/j.purol.2015.08.182. French. No abstract available.


TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model.

Fritsche H, Heilmann T, Tower RJ, Hauser C, von Au A, El-Sheikh D, Campbell GM, Alp G, Schewe D, Hübner S, Tiwari S, Kownatzki D, Boretius S, Adam D, Jonat W, Becker T, Glüer CC, Zöller M, Kalthoff H, Schem C, Trauzold A.

Oncotarget. 2015 Apr 20;6(11):9502-16.


Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.

Haselmann V, Kurz A, Bertsch U, Hübner S, Olempska-Müller M, Fritsch J, Häsler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Röder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Böger C, Knippschild U, Röcken C, Adam D, Walczak H, Schütze S, Janssen O, Wulczyn FG, Wajant H, Kalthoff H, Trauzold A.

Gastroenterology. 2014 Jan;146(1):278-90. doi: 10.1053/j.gastro.2013.10.009. Epub 2013 Oct 9.


A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.

Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr.

Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183. Epub 2013 Aug 26.


Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells.

Fiegl M, Samudio I, Mnjoyan Z, Korchin B, Fritsche H, Andreeff M.

Leukemia. 2010 Jul;24(7):1364-7. doi: 10.1038/leu.2010.94. Epub 2010 May 27. No abstract available.


Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.


American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology.

J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. Review.


Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr.

Gynecol Oncol. 2007 Sep;106(3):490-7. Epub 2007 May 25.


Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K.

Clin Cancer Res. 2007 Feb 1;13(3):920-8.


Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.

Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M.

Cancer. 2007 Feb 1;109(3):496-501.


Translational crossroads for biomarkers.

Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A.

Clin Cancer Res. 2005 Sep 1;11(17):6103-8. Review.


Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.

Breast Cancer Res. 2005;7(4):R436-43. Epub 2005 Apr 8.


Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry.

Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM.

Breast Cancer Res Treat. 2005 Jan;89(2):149-57.


Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer.

Kuerer HM, Coombes KR, Chen JN, Xiao L, Clarke C, Fritsche H, Krishnamurthy S, Marcy S, Hung MC, Hunt KK.

Surgery. 2004 Nov;136(5):1061-9.


A new prognostic model for testicular germ cell tumours.

von Eyben FE, Madsen EL, Fritsche H, Suciu G, Liu F, Amato R.

APMIS. 2003 Jan;111(1):100-5; discussion 105.


Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status.

Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW.

Urology. 2001 Sep;58(3):386-92.


Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors.

von Eyben FE, Blaabjerg O, Hyltoft-Petersen P, Madsen EL, Amato R, Liu F, Fritsche H.

Clin Chem Lab Med. 2001 Jan;39(1):38-44.


2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel.

J Clin Oncol. 2001 Mar 15;19(6):1865-78. Erratum in: J Clin Oncol 2001 Nov 1;19(21):4185-8. J Clin Oncol 2002 Apr 15;20(8):2213.


Supplemental Content

Loading ...
Support Center